Kommentar zu „ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation – executive summary“

[1]  G. Breithardt,et al.  Targeted pharmacological reversal of electrical remodeling after cardioversion--rationale and design of the Flecainide Short-Long (Flec-SL) trial. , 2005, American heart journal.

[2]  R. Hart,et al.  Avoiding Central Nervous System Bleeding During Antithrombotic Therapy: Recent Data and Ideas , 2005, Stroke.

[3]  Paul A Friedman,et al.  Role of permanent pacing to prevent atrial fibrillation: science advisory from the American Heart Association Council on Clinical Cardiology (Subcommittee on Electrocardiography and Arrhythmias) and the Quality of Care and Outcomes Research Interdisciplinary Working Group, in collaboration with the , 2005, Circulation.

[4]  Palle Petersen,et al.  Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. , 2005, JAMA.

[5]  T. Meinertz,et al.  Event‐Recorder Monitoring in the Diagnosis of Atrial Fibrillation in Symptomatic Patients: Subanalysis of the SOPAT Trial , 2006, Journal of cardiovascular electrophysiology.

[6]  S. Hohnloser,et al.  Impact of rate versus rhythm control on quality of life in patients with persistent atrial fibrillation. Results from a prospective randomized study. , 2003, European heart journal.

[7]  C. Lau,et al.  Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion. , 2003, The American journal of cardiology.

[8]  J Clémenty,et al.  Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. , 1998, The New England journal of medicine.

[9]  M. Lesser.  Safety and efficacy of in-office cardioversion for treatment of supraventricular arrhythmias. , 1990, The American journal of cardiology.

[10]  P. Alboni,et al.  Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket" approach. , 2004, The New England journal of medicine.

[11]  J L Cox,et al.  An 8 1/2-year clinical experience with surgery for atrial fibrillation. , 1996, Annals of surgery.

[12]  W. J. Hamilton,et al.  Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial , 1996, The Lancet.

[13]  Douglas L Packer,et al.  Progress in Nonpharmacologic Therapy of Atrial Fibrillation , 2003, Journal of cardiovascular electrophysiology.

[14]  Daniel Steven,et al.  Substrate modification combined with pulmonary vein isolation improves outcome of catheter ablation in patients with persistent atrial fibrillation: a prospective randomized comparison. , 2006, European heart journal.

[15]  R. Cebul,et al.  Limitations of transesophageal echocardiography in the risk assessment of patients before nonanticoagulated cardioversion from atrial fibrillation and flutter: an analysis of pooled trials. , 1995, American heart journal.

[16]  Enalapril treatment and hospitalization with atrial tachyarrhythmias in patients with left ventricular dysfunction. , 2004 .

[17]  G. Breithardt,et al.  Anterior-posterior versus anterior-lateral electrode positions for external cardioversion of atrial fibrillation: a randomised trial , 2002, The Lancet.

[18]  A. Waldo,et al.  Azd7009: a new antiarrhythmic drug with predominant effects on the atria effectively terminates and prevents reinduction of atrial fibrillation and flutter in the sterile pericarditis model. , 2004, Journal of cardiovascular electrophysiology.

[19]  Kenneth A. Ellenbogen,et al.  The Ablate and Pace Trial: A Prospective Study of Catheter Ablation of the AV Conduction System and Permanent Pacemaker Implantation for Treatment of Atrial Fibrillation , 2004, Journal of Interventional Cardiac Electrophysiology.

[20]  B. Lüderitz,et al.  Suppression of paroxysmal atrial tachyarrhythmias — results of the SOPAT trial , 2003 .

[21]  S. Hohnloser,et al.  Rhythm or rate control in atrial fibrillation—Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial , 2000, The Lancet.

[22]  B. Lüderitz,et al.  Suppression of paroxysmal atrial tachyarrhythmias--results of the SOPAT trial. , 2004, European heart journal.

[23]  M. Nieminen,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[24]  Burr Hall,et al.  Catheter Ablation for Paroxysmal Atrial Fibrillation: Segmental Pulmonary Vein Ostial Ablation Versus Left Atrial Ablation , 2003, Circulation.

[25]  S. Lévy,et al.  Low-energy cardioversion of spontaneous atrial fibrillation. Immediate and long-term results. , 1997, Circulation.

[26]  A. Torbicki,et al.  Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) Study. , 2004, Chest.

[27]  U. Tebbe,et al.  Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. , 2003, Journal of the American College of Cardiology.

[28]  R. Cappato,et al.  Efficacy and safety of out-of-hospital self-administered single-dose oral drug treatment in the management of infrequent, well-tolerated paroxysmal supraventricular tachycardia. , 2001, Journal of the American College of Cardiology.

[29]  I. V. Van Gelder,et al.  Safe and effective conversion of persistent atrial fibrillation to sinus rhythm by intravenous AZD7009. , 2006, Heart rhythm.

[30]  G. Breithardt,et al.  A trial of self-adhesive patch electrodes and hand-held paddle electrodes for external cardioversion of atrial fibrillation (MOBIPAPA). , 2005, European heart journal.

[31]  Bruce M Psaty,et al.  Fish intake and risk of incident atrial fibrillation. , 2004, Circulation.

[32]  B. Lüderitz,et al.  Individualized Selection of Pacing Algorithms for the Prevention of Recurrent Atrial Fibrillation: Results from the VIP Registry , 2006 .

[33]  J Clémenty,et al.  Electrophysiological Breakthroughs From the Left Atrium to the Pulmonary Veins , 2000, Circulation.

[34]  L. Goldman,et al.  Quality of life and clinical outcomes in elderly patients treated with ventricular pacing as compared with dual-chamber pacing. , 1998, Pacing and clinical electrophysiology : PACE.

[35]  R. Goldberg,et al.  Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. , 2003, The American journal of cardiology.

[36]  Vincenzo Santinelli,et al.  The Who, What, Why, and How‐To Guide for Circumferential Pulmonary Vein Ablation , 2004, Journal of cardiovascular electrophysiology.

[37]  O. Alfieri,et al.  Atrio-Esophageal Fistula as a Complication of Percutaneous Transcatheter Ablation of Atrial Fibrillation , 2004, Circulation.

[38]  I. V. Van Gelder,et al.  Beta-blockers prevent subacute recurrences of persistent atrial fibrillation only in patients with hypertension. , 2004, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[39]  D. Singer,et al.  An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. , 1996, The New England journal of medicine.

[40]  J. Blanc,et al.  Atrial pacing for prevention of atrial fibrillation: assessment of simultaneously implemented algorithms. , 2004, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[41]  N. Peters,et al.  Atrial fibrillation: strategies to control, combat, and cure , 2002, The Lancet.

[42]  G. Feld,et al.  Control of rapid ventricular response by radiofrequency catheter modification of the atrioventricular node in patients with medically refractory atrial fibrillation. , 1994, Circulation.

[43]  P. McCarthy,et al.  Advances in surgical treatment of atrial fibrillation. , 2004, Stroke.

[44]  P. Jaïs,et al.  Catheter ablation for atrial fibrillation in congestive heart failure , 2005 .

[45]  Holly Yu,et al.  Angiotensin-converting enzyme inhibition in hypertensive patients is associated with a reduction in the occurrence of atrial fibrillation. , 2004, Journal of the American College of Cardiology.

[46]  S. Ernst,et al.  Leitlinien zur Katheterablation , 2007, Clinical Research in Cardiology.

[47]  Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation. A prospective and randomized study ☆ , 2002 .

[48]  L. Rydén,et al.  Chronic atrial fibrillation. Long-term results of direct current conversion. , 2009 .

[49]  B. Lüderitz,et al.  Pro-arrhythmic effects of amiodarone and concomitant rate-control medication. , 2006, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[50]  A. Goldberger,et al.  Cardioversion of atrial fibrillation: consideration of embolization, anticoagulation, prophylactic pacemaker, and long-term success. , 1982, American heart journal.

[51]  A. Laupacis,et al.  A clinical prediction rule to identify patients with atrial fibrillation and a low risk for stroke while taking aspirin. , 2003, Archives of internal medicine.

[52]  Douglas Packer,et al.  Worldwide Survey on the Methods, Efficacy, and Safety of Catheter Ablation for Human Atrial Fibrillation , 2005, Circulation.

[53]  O. Benavente,et al.  Antithrombotic Therapy To Prevent Stroke in Patients with Atrial Fibrillation , 1999, Annals of Internal Medicine.

[54]  G. Breithardt,et al.  Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial. , 2004, European heart journal.

[55]  P. Alboni,et al.  Outpatient treatment of recent-onset atrial fibrillation with the “pill-in-the-pocket” approach , 2005 .

[56]  S. Walsh,et al.  Biphasic energy selection for transthoracic cardioversion of atrial fibrillation. The BEST AF Trial , 2007, Heart.

[57]  H. Crijns,et al.  Chronic atrial fibrillation. Success of serial cardioversion therapy and safety of oral anticoagulation. , 1996, Archives of internal medicine.

[58]  Otto Kamp,et al.  Effect of rate or rhythm control on quality of life in persistent atrial fibrillation. Results from the Rate Control Versus Electrical Cardioversion (RACE) Study. , 2004, Journal of the American College of Cardiology.

[59]  J. Boineau,et al.  The long-term outcome of patients with coronary disease and atrial fibrillation undergoing the Cox maze procedure. , 2003, The Journal of thoracic and cardiovascular surgery.

[60]  M. Domanski,et al.  Relationships Between Sinus Rhythm, Treatment, and Survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study , 2004, Circulation.

[61]  R. Steeds,et al.  An open label, randomised, crossover study comparing sotalol and atenolol in the treatment of symptomatic paroxysmal atrial fibrillation , 1999, Heart.

[62]  A. Camm,et al.  Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. , 1999, The New England journal of medicine.

[63]  M Gent,et al.  Effects of physiologic pacing versus ventricular pacing on the risk of stroke and death due to cardiovascular causes , 2000 .

[64]  F. Loop,et al.  Role of prophylactic anticoagulation for direct current cardioversion in patients with atrial fibrillation or atrial flutter. , 1992, Journal of the American College of Cardiology.

[65]  Kenneth Egstrup,et al.  Effect of dofetilide in patients with recent myocardial infarction and left-ventricular dysfunction: a randomised trial , 2000, The Lancet.

[66]  J. Boineau,et al.  Modification of the maze procedure for atrial flutter and atrial fibrillation. I. Rationale and surgical results. , 1995, The Journal of thoracic and cardiovascular surgery.

[67]  J. Tijssen,et al.  Recurrence of paroxysmal atrial fibrillation or flutter after successful cardioversion in patients with normal left ventricular function. , 1993, The American journal of cardiology.

[68]  S. Husted,et al.  Long-term anticoagulant therapy in patients with coronary artery disease. , 2006, European heart journal.

[69]  Atul Verma,et al.  Pulmonary Vein Antrum Isolation: , 2004, Journal of cardiovascular electrophysiology.

[70]  B. Olshansky,et al.  Heart Failure and Sudden Death in Patients With Tachycardia-Induced Cardiomyopathy and Recurrent Tachycardia , 2004, Circulation.

[71]  O. Orning,et al.  The efficacy of anticoagulant therapy in preventing embolism related to D.C. electrical conversion of atrial fibrillation. , 1969, The American journal of cardiology.

[72]  M. Brignole,et al.  Assessment of atrioventricular junction ablation and DDDR mode-switching pacemaker versus pharmacological treatment in patients with severely symptomatic paroxysmal atrial fibrillation: a randomized controlled study. , 1997, Circulation.

[73]  R. Page,et al.  Initial energy for elective external cardioversion of persistent atrial fibrillation. , 2000, The American journal of cardiology.

[74]  S. Hohnloser,et al.  Atrial Fibrillation and Congestive Heart Failure: Specific Considerations at the Intersection of Two Common and Important Cardiac Disease Sets , 2002, Journal of cardiovascular electrophysiology.

[75]  J. Cox.  Cardiac surgery for arrhythmias. , 2004, Journal of cardiovascular electrophysiology.

[76]  L. Goldman,et al.  Ventricular pacing or dual-chamber pacing for sinus-node dysfunction. , 2002, The New England journal of medicine.

[77]  S. Kjeldsen,et al.  Prevention of new-onset atrial fibrillation and its predictors with angiotensin II-receptor blockers in the treatment of hypertension and heart failure , 2007, Journal of hypertension.

[78]  M. Nieminen,et al.  Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. , 2005, Journal of the American College of Cardiology.

[79]  S. Lévy,et al.  Multicenter low energy transvenous atrial defibrillation (XAD) trial results in different subsets of atrial fibrillation. , 1997, Journal of the American College of Cardiology.

[80]  R McBride,et al.  Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. , 1999, Stroke.

[81]  C. White,et al.  The Impact of Suppressing the Renin‐Angiotensin System on Atrial Fibrillation , 2006, Journal of clinical pharmacology.

[82]  M. Pfeffer,et al.  Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. , 2006, Journal of the American College of Cardiology.

[83]  M. Niebauer,et al.  Radiofrequency catheter modification of atrioventricular conduction to control the ventricular rate during atrial fibrillation. , 1994, The New England journal of medicine.

[84]  S. Yusuf,et al.  Clinical ResearchHeart Rhythm DisorderPrevention of Atrial Fibrillation With Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: A Meta-Analysis , 2005 .

[85]  K. Stangl,et al.  Use of metoprolol CR/XL to maintain sinus rhythm after conversion from persistent atrial fibrillation: a randomized, double-blind, placebo-controlled study. , 2000, Journal of the American College of Cardiology.

[86]  M. Pfeffer,et al.  Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial , 2006, The Lancet.

[87]  Mandeep Bhargava,et al.  Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial. , 2005, JAMA.

[88]  Gianni Tognoni,et al.  Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). , 2005 .

[89]  H. Crijns,et al.  A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation , 2002 .

[90]  F. Morady,et al.  Facilitating transthoracic cardioversion of atrial fibrillation with ibutilide pretreatment. , 1999, The New England journal of medicine.

[91]  James B Seward,et al.  The prevalence of atrial fibrillation in incident stroke cases and matched population controls in Rochester, Minnesota: changes over three decades. , 2003, Journal of the American College of Cardiology.

[92]  Efficacy of Biphasic Shock for Transthoracic Cardioversion of Persistent Atrial Fibrillation: , 2004 .

[93]  A. d'Avila,et al.  Left Atrial–Esophageal Fistula Following Radiofrequency Catheter Ablation of Atrial Fibrillation , 2004, Journal of cardiovascular electrophysiology.

[94]  Martha J. Radford,et al.  Validation of Clinical Classification Schemes for Predicting Stroke: Results From the National Registry of Atrial Fibrillation , 2001 .

[95]  B. Schumacher,et al.  Bimodal RR Interval Distribution in Chronic Atrial Fibrillation: , 2000, Journal of cardiovascular electrophysiology.

[96]  Prashanthan Sanders,et al.  Catheter ablation for atrial fibrillation in congestive heart failure. , 2004, The New England journal of medicine.

[97]  P C Deedwania,et al.  Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. , 1995, The New England journal of medicine.

[98]  P. Hasselgren,et al.  The selective beta 1-blocking agent metoprolol compared with antithyroid drug and thyroxine as preoperative treatment of patients with hyperthyroidism. Results from a prospective, randomized study. , 1987, Annals of surgery.

[99]  V. Fuster,et al.  Management of patients with atrial fibrillation. A Statement for Healthcare Professionals. From the Subcommittee on Electrocardiography and Electrophysiology, American Heart Association. , 1996, Circulation.

[100]  M. Jazayeri,et al.  The Impact of Atrial Prevention and Termination Therapies on Atrial Tachyarrhythmia Burden in Patients Receiving a Dual-Chamber Defibrillator for Ventricular Arrhythmias , 2004, Journal of Interventional Cardiac Electrophysiology.

[101]  Margaret C Fang,et al.  Advanced Age, Anticoagulation Intensity, and Risk for Intracranial Hemorrhage among Patients Taking Warfarin for Atrial Fibrillation , 2004, Annals of Internal Medicine.

[102]  L. Køber,et al.  Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. , 1999, Circulation.

[103]  Katherine E. Harris,et al.  Stroke Reduction in Hypertensive Adults With Cardiac Hypertrophy Randomized to Losartan Versus Atenolol: The Losartan Intervention For Endpoint Reduction in Hypertension Study , 2005, Hypertension.

[104]  G. Kay,et al.  Clinical outcomes after ablation and pacing therapy for atrial fibrillation : a meta-analysis. , 2000, Circulation.

[105]  J. Halperin,et al.  Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. , 2001, The New England journal of medicine.

[106]  M. Brignole,et al.  Assessment of atrioventricular junction ablation and VVIR pacemaker versus pharmacological treatment in patients with heart failure and chronic atrial fibrillation: a randomized, controlled study. , 1998, Circulation.

[107]  L. Thuesen,et al.  Long-term follow-up of patients from a randomised trial of atrial versus ventricular pacing for sick-sinus syndrome , 1997, The Lancet.

[108]  A L Waldo,et al.  A comparison of rate control and rhythm control in patients with atrial fibrillation. , 2002, The New England journal of medicine.